Related Experiment Video

Updated: Aug 25, 2026

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
08:27

Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology

Published on: March 24, 2015

HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients

Yuki Ishihara1, Mamoru Harada, Koichi Azuma

  • 1Department of Immunology, Kurume University School of Medicine, Kurume 830-0011, Japan.

International Journal of Oncology
|March 11, 2004
PubMed

Insights

Researchers identified three HER2/neu-derived peptides that trigger both humoral and cellular immune responses. These peptides show promise for developing novel peptide-based immunotherapies for HLA-A2+ cancer patients.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • HER2/neu is a validated target antigen for anti-cancer therapies due to its expression in various epithelial cancers.
  • HER2/neu is recognized by both cellular and humoral immune responses, making it a promising candidate for immunotherapy.

Purpose of the Study:

  • To identify HER2/neu-derived peptides recognized by both humoral and cellular immune systems in HLA-A2+ cancer patients.
  • To evaluate the potential of these peptides for developing peptide-based cancer immunotherapy.

Main Methods:

  • Analysis of 12 HER2/neu-derived peptides with HLA-A2 binding motifs.
  • Detection of immunoglobulin G reactivity in cancer patient plasma against HER2/neu peptides.
  • Assessment of peptide-specific and HLA-A2-restricted cytotoxic T lymphocyte activity using peripheral blood mononuclear cells.
  • Characterization of cytotoxicity using blocking antibodies and cold inhibition targets.

Main Results:

  • Immunoglobulin G reactivity was detected in over 50% of cancer patients against 7 out of 12 tested HER2/neu peptides.
  • Three specific peptides (HER2/neu 444-452, 466-474, and 484-492) induced significant peptide-specific, HLA-A2-restricted cytotoxic T lymphocyte activity.
  • Cytotoxicity against HER2/neu-expressing tumor cells was confirmed as peptide-specific and CD8+ T cell-dependent.

Conclusions:

  • The identified HER2/neu peptides are effectively recognized by both humoral and cellular immune systems.
  • These peptides represent potential candidates for peptide-based immunotherapy in HLA-A2+ patients with epithelial cancers.
  • Further development of these peptides could lead to novel therapeutic strategies for a range of cancers.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Related Concept Videos

Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Antigen Processing Pathways01:31

Antigen Processing Pathways

MHC molecules are key players in the immune response, enabling T cells to recognize and respond to specific antigens. They are present on the surface of all nucleated cells in the body and are instrumental in presenting antigens to T cells and activating them. T cells recognize the MHC-antigen complex and initiate an immune response. MHC class I and MHC class II are two main types of MHC molecules, each associated with a distinct antigen processing pathway.
MHC Class I: Presenting Endogenous...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...